Einsatz von niederosmolarem Gadolinium zur angiographischen Darstellung und bei interventionell-radiologischen Eingriffen bei niereninsuffizienten Patienten

Dinkel, Hans-Peter; Hoppe, Hanno; Baumgartner, Iris; D., D.; Triller, J

doi:10.1055/s-2002-19535

Cited by 9 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of distal protection devices is limited by the anatomy of the renal artery 74 . To avoid contrast‐induced nephropathy, nowadays carbon dioxide or gadodiamide can be used as alternative contrast agents if digital subtraction technique is available 75–78 . Furthermore, the development of less nephrotoxic contrast agents such as iodixanol (an iso‐osmolar, nonionic‐iodinated contrast agent), nephroprotective agents, and pre‐ and postinterventional hydration of the patient have also led to a reduction of the frequency of contrast nephropathy 79–81 …”

Section: Technique Of Percutaneous Transluminal Renal Angioplastymentioning

confidence: 99%

Renal Artery Stenosis: Epidemiology, Clinical Manifestation, and Percutaneous Endovascular Therapy

Zeller¹

2005

J Interven Cardiology

View full text Add to dashboard Cite

Renal artery stenosis may cause or deteriorate arterial hypertension and/or renal insufficiency. Technical improvements of diagnostic and interventional endovascular tools have lead to a more widespread use of endoluminal renal artery revascularization and extension of the indications for this type of therapy. Since the first renal artery angioplasties performed by Felix Mahler and Andreas Grüntzig in 1978, numerous single-center studies have reported the beneficial effect of percutaneous transluminal renal angioplasty, and since the early 1990's stenting of renal artery stenosis caused either by atherosclerosis or by fibromuscular dysplasia. This article summarizes the impact of technical improvements of endovascular tools on interventional techniques during the last decade and gives an overview concerning the clinical impact of renal artery revascularization. Despite the absence of sufficient randomized studies, there is nonetheless evidence that stenting of hemodynamically relevant atherosclerotic renal artery stenosis has an impact on blood pressure control, renal function, and left ventricular hypertrophy.

show abstract

Section: Technique Of Percutaneous Transluminal Renal Angioplastymentioning

confidence: 99%

Renal Artery Stenosis: Epidemiology, Clinical Manifestation, and Percutaneous Endovascular Therapy

Zeller¹

2005

J Interven Cardiology

View full text Add to dashboard Cite

show abstract

Actual clinical use of gadolinium-chelates for non-MRI applications

Strunk

Schild

2004

European Radiology

View full text Add to dashboard Cite

For many years, alternatives to iodinated X-ray contrast media have been sought. Of the contrast media investigated to date, only CO(2) and the gadolinium-chelates have been shown to be viable alternatives for selected X-ray examinations. Therefore, we have reviewed the general literature and that specific for gadopentetate (Magnevist) in particular, since this agent has been studied the most. This review indicates that diagnostic CT examinations can be achieved following the intravenous administration of gadolinium-containing contrast media (CM) for evaluation of aortic abnormalities. Gadolinium-containing CM at the dose approved for MR imaging are not useful for CT evaluation of the abdominal parenchymal organs. Intravenous/intraarterial injections have also been used in a variety of angiographic and interventional procedures. Image quality, however, is generally inferior to iodinated contrast media. Gadolinium-containing CM require no special handling and can be administered by hand injection or via conventional angiographic automated injectors with the same flow rates and pressures as are used with iodinated contrast media. For CT, a peripheral bolus injection of a diluted gadolinium agent (1:1 with saline) of 60-90 ml at 3-5 ml/s is usually performed. Similar to all other gadolinium-chelates, the non-MRI use of gadopentetate (Magnevist) is not approved by regulatory agencies. However, the literature suggests that a dose of 0.3-0.4 mmol/kg b.w. has been safely administered for CT as well as for angiography and interventional procedures intravenously and intraarterially. Even at this dose, though, this results in a relatively small overall volume to be injected, which limits utility somewhat.

show abstract

Adverse Events Associated with Intra-Arterial Administration of Gadolinium-Based Contrast Agents: A Systematic Review and Meta-Analysis

Macleod

Gauthier

Davenport

et al. 2023

Journal of Vascular and Interventional Radiology

View full text Add to dashboard Cite

Einsatz von niederosmolarem Gadolinium zur angiographischen Darstellung und bei interventionell-radiologischen Eingriffen bei niereninsuffizienten Patienten

Abstract: Gadolinium is a viable alternative contrast agent for digital subtraction angiography and percutaneous transluminal angioplasty in patients with renal insufficiency. It enhances the diagnostic evaluation of stenosis and run-off vessels.

Cited by 9 publications

References 23 publications

Renal Artery Stenosis: Epidemiology, Clinical Manifestation, and Percutaneous Endovascular Therapy

Renal Artery Stenosis: Epidemiology, Clinical Manifestation, and Percutaneous Endovascular Therapy

Actual clinical use of gadolinium-chelates for non-MRI applications

Adverse Events Associated with Intra-Arterial Administration of Gadolinium-Based Contrast Agents: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About